Please login to the form below

Genmab

This page shows the latest Genmab news and features for those working in and with pharma, biotech and healthcare.

Janssen scores another expansion for new Darzalex combination in the US

Darzalex, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.

Latest news

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

Janssen developed JNJ-6372 in collaboration with Genmab, which is also its collaborator on blockbuster multiple myeloma therapy Darzalex (daratumumab) and follow-up HexaBody-CD38.
BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

lagging behind rivals in the market such as Johnson &Johnson and Genmab’s CD38 inhibitor Darzalex (daratumumab). ... Earlier this month, Sanofi claimed FDA approval for Sarclisa (isatuximab) in relapsed/refractory myeloma, while J&J and Genmab already
GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK is just the latest in a series of drugmakers to cut deals with Immatics for access to its cell therapy expertise, and it has previously partnered withRoche and Genmab.
Janssen files new Darzalex combination for multiple myeloma

Darzalex, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.
J&J wins another label expansion for Darzalex in Europe

The drug, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.

More from news
Approximately 7 fully matching, plus 46 partially matching documents found.

Latest Intelligence

European biotech: a new generation of leaders emerges

Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease. ... If approved, this would become Genmab’s third product on the market, behind Darzalex and
Deal Watch August 2016

469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.
Pharma deals in August 2015

Exclusive global licence. 510. Genmab. Novo Nordisk. Bispecific antibody candidates outside oncology indications.
Deal Watch table for September 2014

244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
Pharma deals during September 2014

Four years ago Genmab started working with Seattle Genetics' ADC technology and has now signed a new deal using a Genmab antibody. The creative aspect of this deal is that Seattle ... has retained an option to increase the Genmab royalties to double

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Genmab hires first chief operating officer

In his new role, Mancini will oversee all of Genmab’s commercial, corporate development, business development and information technology functions. ... operations during this transformational stage for Genmab,”said Jan van de Winkel, chief executive
EUSA Pharma appoints Rolf Hoffmann to its board

Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number
Dr Jan van de Winkel joins Austrian biotech Hookipa

Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’ experience in the therapeutic antibody field. ... Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice
Former Novartis exec joins Genmab

Dr Judith Klimovsky becomes chief development officer. Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer. ... Jan van de Winkel, Genmab's chief executive, said: “We are very
bmore creative hires Kush Rach as new business director

at Charles River Laboratories, where he worked on clinical trial programmes for Ferring, Genmab, AstraZeneca, and Aerocrine (spending much of his time in Scandinavia).

More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Account Director: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Lead Copywriter: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

PMHub

Add my company

KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

The pandemic preparedness paradox: Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...